For the quarter ended September 2025, Astrazeneca (AZN Quick QuoteAZN - Free Report) reported revenue of $15.19 billion, up 12% over the same period last year. EPS came in at $1.19, compared to $1.04 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $14.87 billion, representing a surprise of +2.13%. The company delivered an EPS surprise of +4.39%, with the consensus EPS estimate being $1.14.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Astrazeneca performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• BioPharmaceuticals- R&I- Symbicort- U.S.: $305 million compared to the $302.37 million average estimate based on three analysts. The reported number represents a change of +5.5% year over year.
• BioPharmaceuticals- R&I- Fasenra- Europe: $122 million versus $118.21 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +19.6% change.
• Oncology- Europe: $1.28 billion versus the three-analyst average estimate of $1.22 billion. The reported number represents a year-over-year change of +24.4%.
• Oncology- Enhertu- Established RoW: $21 million versus the three-analyst average estimate of $23.89 million. The reported number represents a year-over-year change of +31.3%.
• BioPharmaceuticals- R&I- Symbicort- World: $742 million versus the three-analyst average estimate of $707 million. The reported number represents a year-over-year change of +5.3%.
• BioPharmaceuticals- R&I- Pulmicort- World: $93 million versus the three-analyst average estimate of $98.65 million. The reported number represents a year-over-year change of -32.6%.
• BioPharmaceuticals- CVRM- Crestor- World: $305 million versus the three-analyst average estimate of $320.61 million. The reported number represents a year-over-year change of +0.3%.
• BioPharmaceuticals- CVRM- Seloken/Toprol-XL- World: $160 million compared to the $142.46 million average estimate based on three analysts. The reported number represents a change of +6.7% year over year.
• Oncology- Tagrisso- World: $1.86 billion compared to the $1.85 billion average estimate based on three analysts. The reported number represents a change of +11.4% year over year.
• BioPharmaceuticals- V&I- Synagis- World: $58 million versus $69.33 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -37.6% change.
• BioPharmaceuticals- R&I- Fasenra- World: $530 million versus the three-analyst average estimate of $498.02 million. The reported number represents a year-over-year change of +21.6%.
• BioPharmaceuticals- CVRM- Brilinta- World: $146 million compared to the $170.12 million average estimate based on three analysts. The reported number represents a change of -55.4% year over year.

View all Key Company Metrics for Astrazeneca here>>>

Shares of Astrazeneca have returned -5% over the past month versus the Zacks S&P 500 composite's +1.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.